Hangzhou Bio-Sincerity Pharma-TechLtd Balance Sheet Health
Financial Health criteria checks 4/6
Hangzhou Bio-Sincerity Pharma-TechLtd has a total shareholder equity of CN¥2.8B and total debt of CN¥598.8M, which brings its debt-to-equity ratio to 21.6%. Its total assets and total liabilities are CN¥3.8B and CN¥989.8M respectively. Hangzhou Bio-Sincerity Pharma-TechLtd's EBIT is CN¥174.2M making its interest coverage ratio -52.1. It has cash and short-term investments of CN¥462.0M.
Key information
21.6%
Debt to equity ratio
CN¥598.85m
Debt
| Interest coverage ratio | -52.1x |
| Cash | CN¥461.99m |
| Equity | CN¥2.77b |
| Total liabilities | CN¥989.80m |
| Total assets | CN¥3.76b |
Recent financial health updates
No updates
Recent updates
We Believe That Hangzhou Bio-Sincerity Pharma-TechLtd's (SZSE:301096) Weak Earnings Are A Good Indicator Of Underlying Profitability
Nov 04
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SZSE:301096) Soars 30% But It's A Story Of Risk Vs Reward
Sep 30Market Cool On Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s (SZSE:301096) Earnings Pushing Shares 27% Lower
Jul 24Solid Earnings May Not Tell The Whole Story For Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096)
Apr 29Should You Be Adding Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096) To Your Watchlist Today?
Mar 14Financial Position Analysis
Short Term Liabilities: 301096's short term assets (CN¥1.6B) exceed its short term liabilities (CN¥821.9M).
Long Term Liabilities: 301096's short term assets (CN¥1.6B) exceed its long term liabilities (CN¥167.9M).
Debt to Equity History and Analysis
Debt Level: 301096's net debt to equity ratio (4.9%) is considered satisfactory.
Reducing Debt: 301096's debt to equity ratio has increased from 1.3% to 21.6% over the past 5 years.
Debt Coverage: 301096's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: 301096 earns more interest than it pays, so coverage of interest payments is not a concern.